LABCORP HOLDINGS INC. LH

The strongest supplied fact is still the filed quarter: Labcorp reported $3.54B of revenues, $380.8M of operating income, $277.8M of net income attributable to the parent and diluted earnings per share of $3.35 for the 10-Q period ended March 31, 2026. That gives today’s LH file a real operating base rather than a loose healthcare technology story.

Labcorp is presented on the official issuer rail as a laboratory diagnostics, drug development and global life sciences business. The supplied product evidence connects that identity to MyLabcorp for patient results and trends, an AI-enhanced Test Finder integrated into EHRs through Labcorp Diagnostic Assistant and Labcorp Link, and an AI-powered platform developed with Amazon Web Services and Datavant for longitudinal laboratory data and analytics.

The 10-Q evidence says Dx and BLS contributed approximately 78% and 22% of revenue, respectively, during the three months ended March 31, 2026 and 2025. It also says U.S. revenues were $2,914.0M, or 82.4%, for the three months ended March 31, 2026, compared with $2,813.8M, or 84.1%, for the three months ended March 31, 2025. The balance sheet rail shows $19.09B of assets, $10.34B of liabilities, $8.73B of stockholders’ equity attributable to the parent and $981.1M of cash and cash equivalents at March 31, 2026.

The supplied source list does not include a chart route or traded price levels, so the market mechanism here has to stay anchored in filings, official issuer evidence and named public developments. The relevant public paper includes a May 27, 2026 8-K saying Labcorp would present at the 2026 Jefferies Healthcare Conference in New York on June 3, 2026, plus SEC filings listed as a June 10 Form 4, a June 8 Form 144, a May 26 8-K, a May 22 SD filing and a May 13 Form 4.

What changed on this rail is not a new financial result today, but a run of official disclosures after the May 4 10-Q and a product story that ties laboratory operations to data access and clinical search tools. What remains unproven from the supplied evidence is price action, guidance, order trends, customer adoption, margin direction beyond the filed quarter, and the business impact of the AI platform or Test Finder integrations.